Frontlight ResearchEarly access
Metastatic breast cancer trials in Australia
36 trials · From ClinicalTrials.gov, checked 16 November 2026. Ask the study team whether a trial fits you.
- Phase 1Taking peopleBGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer
- Where
- Birtinya, Darlinghurst, Melbourne, Nedlands, St Albans, Waratah
- Age
- 18 years and over
- People
- 120 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT06756932 - Phase 1/2Taking peopleStudy of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
- Where
- Clayton, Melbourne
- Age
- 18 years to 100 years
- People
- 280 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT06726148 · EU 2024-517281-42-00 - Phase 1/2Taking peopleA Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
- Where
- Melbourne, Sydney
- Age
- 18 years and over
- People
- 270 worldwide
- Run by
- Lumara Bio Oncologics GmbH
See details and how to joinNCT05706129 · EU 2023-504254-35-00 - Phase 3TerminatedTrastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
- Where
- Adelaide, East Bentleigh, Murdoch, North Sydney
- Age
- 18 years and over
- People
- 250 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT05950945 · EU 2023-505616-38-00 - Early phase 1Taking peopleFirst-in-human Diagnostic Imaging Profile of the Theranostic Pair [68Ga]Ga-DOTA-STR-17126 and Low Dose [177Lu] Lu-DOTA-STR-17126 in Patients With Advanced or Metastatic Cancer
- Where
- Perth
- Age
- 18 years and over
- People
- 20
- Run by
- Integrated Haematology and Oncology Network
See details and how to joinNCT07608848 - Phase 1Taking peopleA Phase 1 Trial of ERX-315 in Participants With Advanced Solid Tumors
- Where
- Adelaide, Ryde, Sydney, Westmead
- Age
- 18 years and over
- People
- 36
- Run by
- EtiraRx Australia Pty Ltd
See details and how to joinNCT06533332 - Phase 1/2Taking peopleOpen-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
- Where
- Frankston, Parkville, South Brisbane
- Age
- 18 years and over
- People
- 150 worldwide
- Run by
- Incyclix Bio
See details and how to joinNCT05735080 - Phase 1Taking peopleSapu003 in Advanced mTOR-sensitive Solid Tumors
- Where
- Adelaide
- Age
- 18 years and over
- People
- 27
- Run by
- SAPU NANO (US) LLC
See details and how to joinNCT07369505 - Phase 1Taking peopleFirst-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
- Where
- Melbourne, Sydney
- Age
- 18 years and over
- People
- 930 worldwide
- Run by
- Relay Therapeutics, Inc.
See details and how to joinNCT05216432 - Phase 1/2Taking peopleSeviteronel in Combination With Chemotherapy in Androgen-receptor Positive Metastatic Triple-negative Breast Cancer
- Where
- Darlinghurst
- Age
- 18 years and over
- People
- 65
- Run by
- St Vincent's Hospital, Sydney
See details and how to joinNCT04947189 - No phaseNot yet taking people in AustraliaStudy Investigating the Role of Routine Screening and Molecular Characterisation of Brain Metastasis in the Management of High-risk Metastatic Breast Cancer
- Where
- Melbourne
- Age
- 18 years and over
- People
- 45
- Run by
- Monash University
See details and how to joinNCT06728150